Severe developmental disorders (DDs) are frequently caused by de novo mutations (DNMs) in dominant, developmentally important genes. The Deciphering Developmental Disorders (DDD) study's 2017 analysis of 4,293 exome-sequenced families (meta-analysed with 3,287 published individuals) showed that DNMs account for roughly half of the genetic architecture of severe DDs, identified 94 DNM-enriched genes, and estimated that about 42% of the cohort carried a pathogenic coding DNM, split approximately equally between loss-of-function and altered-function mechanisms. The same analysis exposed two linked gaps that define this problem: most haploinsufficient DD genes had already been found, but many genes whose pathogenicity is mediated by missense (altered-function) DNMs remain undiscovered; and the penetrance of DNMs in the genome-wide significant genes could not be formally assessed. Molecular mechanism, by contrast, was estimated only cohort-wide, as a loss-of-function versus altered-function split. Later work — trio cohorts of 31,058 to 43,287 families, depletion-based constraint methods (gnomAD, Gnocchi, GeneBayes), the noncoding RNU4-2 discovery, gene-level mechanism prevalence estimates, and population-cohort evidence for incomplete penetrance — has advanced both threads without closing either: consortium modelling still implies more than 1,000 undiscovered DD genes, and per-gene DNM penetrance remains unquantified. The problem is open.

Background

A de novo mutation (DNM) is a genetic variant present in a child but absent from the genomes of both parents; because such variants cannot be filtered by family history, they are found by trio sequencing — sequencing an affected child and both parents. In developmental disorders (DDs), a clinical grouping of severe, early-onset conditions including global developmental delay, intellectual disability, epilepsy and congenital anomalies, exome sequencing (the ~1–2% of the genome encoding proteins) of parent–child trios has been the main discovery tool since about 2010. DNMs in coding sequence are the largest single identified cause of severe DD.

The statistical machinery of DNM-based gene discovery compares, gene by gene, the number of damaging DNMs observed in cases with the number expected under a mutation-rate model that accounts for gene length, local sequence context and regional mutation-rate features — the interpretive framework formalized by Samocha et al. (2014). Protein-truncating variants typically cause dominant disease by loss of function (LoF), i.e. haploinsufficiency, in which one functional copy of the gene is not enough; such genes are depleted of truncating variation in large population catalogs such as ExAC/gnomAD, quantified by intolerance metrics (for example pLI), and this depletion is itself informative about disease-gene status. Missense variants (single amino-acid substitutions) can instead act by altered-function mechanisms — gain-of-function (new or increased activity) or dominant-negative (the mutant protein interferes with the normal one) — and genes of this class tend to be depleted of damaging missense variation in the population and to show spatial clustering of pathogenic missense changes within protein domains.

The Deciphering Developmental Disorders (DDD) study, a UK-and-Ireland consortium that recruited and systematically phenotyped thousands of families with severe undiagnosed DDs, established the quantitative landscape in its 2017 analysis (following its first large gene-discovery paper in 2015). It identified 94 genes enriched for damaging DNMs (14 without previous compelling evidence), showed that diagnostic yield depends on the sex of the affected individual, parental relatedness, affected close relatives and parental ages, and estimated that about 42% of the cohort carried a pathogenic coding DNM, with mechanisms split roughly half loss-of-function and half altered-function; the average birth prevalence of dominant DNM-caused DD was estimated at about 1 in 295 (1 in 213 to 1 in 448 depending on parental age). A decisive asymmetry emerged: about 71% of the excess truncating DNMs hit known DD genes, but only about 42% of the excess missense DNMs did. The authors concluded that most haploinsufficient DD genes had already been identified, whereas many genes driven by pathogenic missense DNMs — acting through activating or dominant-negative mechanisms, with each disorder individually rarer and caused by relatively few missense changes per gene — had eluded discovery. The field has since framed the collective objective as completing the map of genes associated with developmental disorders.

Problem Statement

The problem, as posed by the DDD study's 2017 analysis and restated by its successors, is to complete the dominant de novo genetic architecture of severe developmental disorders by delivering two linked results: (1) identification of the remaining dominant DD-associated genes — expected to be predominantly those in which pathogenicity is mediated by a small number of missense DNMs acting through altered-function (activating or dominant-negative) mechanisms; and (2) formal estimation of the penetrance of pathogenic DNMs in the DD-associated genes identified at genome-wide significance. Mechanism class (loss-of-function versus altered-function) enters here as a property of the genes to be identified — the source estimated it cohort-wide and framed understanding it as a prerequisite for designing therapeutic strategies — rather than as a separately specified deliverable. One instrumental sub-question supports these deliverables: improved analytical integration of accurate, complete quantitative and categorical phenotypic data to boost power for detecting ultrarare, clinically distinctive disorders.

References

  1. Deciphering Developmental Disorders Study. Prevalence and architecture of de novo mutations in developmental disorders. Nature 542(7642):433-438, 2017. DOI: 10.1038/nature21062. https://doi.org/10.1038/nature21062
  2. Deciphering Developmental Disorders Study. Large-scale discovery of novel genetic causes of developmental disorders. Nature 519(7542):223-228, 2015. DOI: 10.1038/nature14135. https://doi.org/10.1038/nature14135
  3. Samocha KE, Robinson EB, Sanders SJ, et al. A framework for the interpretation of de novo mutation in human disease. Nature Genetics 46(9):944-950, 2014. DOI: 10.1038/ng.3050. https://doi.org/10.1038/ng.3050
  4. Kaplanis J, Samocha KE, Wiel L, et al. Evidence for 28 genetic disorders discovered by combining healthcare and research data. Nature 586(7831):757-762, 2020. DOI: 10.1038/s41586-020-2832-5. https://doi.org/10.1038/s41586-020-2832-5
  5. Hamanaka K, Miyake N, Mizuguchi T, et al. Large-scale discovery of novel neurodevelopmental disorder-related genes through a unified analysis of single-nucleotide and copy number variants. Genome Medicine 14(1):40, 2022. DOI: 10.1186/s13073-022-01042-w. https://doi.org/10.1186/s13073-022-01042-w
  6. Zhou X, Feliciano P, Shu C, et al. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nature Genetics 54:1305-1319, 2022. DOI: 10.1038/s41588-022-01148-2. https://doi.org/10.1038/s41588-022-01148-2
  7. Kealhofer M, Brown R, Riley BP, Nguyen T-H. Joint analysis of de novo mutations from autism spectrum disorder, schizophrenia, congenital heart disease, and other developmental disorders improves detection power and implicates shared molecular pathways and CNS processes. NAR Genomics and Bioinformatics 7(4):lqaf162, 2025. DOI: 10.1093/nargab/lqaf162. https://doi.org/10.1093/nargab/lqaf162
  8. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581(7809):434-443, 2020. DOI: 10.1038/s41586-020-2308-7. https://doi.org/10.1038/s41586-020-2308-7
  9. Chen S, Francioli LC, Goodrich JK, et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625(7993):92-100, 2024. DOI: 10.1038/s41586-023-06045-0. https://doi.org/10.1038/s41586-023-06045-0
  10. Zeng T, Spence JP, Mostafavi H, Pritchard JK. Bayesian estimation of gene constraint from an evolutionary model with gene features. Nature Genetics 56(8):1632-1643, 2024. DOI: 10.1038/s41588-024-01820-9. https://doi.org/10.1038/s41588-024-01820-9
  11. Chen Y, Dawes R, Kim HC, et al. De novo variants in the RNU4-2 snRNA cause a frequent neurodevelopmental syndrome. Nature 632(8026):832-840, 2024. DOI: 10.1038/s41586-024-07773-7. https://doi.org/10.1038/s41586-024-07773-7
  12. Kingdom R, Tuke M, Wood A, Beaumont RN, Frayling TM, Weedon MN, Wright CF. Rare genetic variants in genes and loci linked to dominant monogenic developmental disorders cause milder related phenotypes in the general population. American Journal of Human Genetics 109(7):1308-1316, 2022. DOI: 10.1016/j.ajhg.2022.05.011. https://doi.org/10.1016/j.ajhg.2022.05.011
  13. Wigdor EM, Samocha KE, Eberhardt RY, et al. Investigating the role of common cis-regulatory variants in modifying penetrance of putatively damaging, inherited variants in severe neurodevelopmental disorders. Scientific Reports 14:8708, 2024. DOI: 10.1038/s41598-024-58894-y. https://doi.org/10.1038/s41598-024-58894-y
  14. Badonyi M, Marsh JA. Prevalence of loss-of-function, gain-of-function and dominant-negative mechanisms across genetic disease phenotypes. Nature Communications 16:8392, 2025. DOI: 10.1038/s41467-025-63234-3. https://doi.org/10.1038/s41467-025-63234-3
  15. Radford EJ, Tan HK, Andersson MHL, et al. Saturation genome editing of DDX3X clarifies pathogenicity of germline and somatic variation. Nature Communications 14:7702, 2023. DOI: 10.1038/s41467-023-43041-4. https://doi.org/10.1038/s41467-023-43041-4
  16. Ng JK, Chen Y, Akinwe TM, et al. Proteome-wide assessment of differential missense variant clustering in neurodevelopmental disorders and cancer. Cell Genomics 5(4):100807, 2025. DOI: 10.1016/j.xgen.2025.100807. https://doi.org/10.1016/j.xgen.2025.100807
  17. Aitken S, Firth HV, Wright CF, Hurles ME, FitzPatrick DR, Semple CA. IMPROVE-DD: Integrating multiple phenotype resources optimizes variant evaluation in genetically determined developmental disorders. HGG Advances 4:100162, 2023. DOI: 10.1016/j.xhgg.2022.100162. https://doi.org/10.1016/j.xhgg.2022.100162